Abstract:Background The aim of this study was to characterize the variable phenotypes and outcomes associated with the methylmalonic aciduria and homocystinuria type C protein gene (MMACHC) c.482G > A mutation in 195 Chinese cases with CblC disease.Methods We carried out a national, retrospective multicenter study of 195 Chinese patients with CblC disease attributable to the MMACHC c.482G > A variant either in a homozygous or compound heterozygous state. The control group consisted of 200 patients diagnosed with CblC disease who did not possess the c.482G > A mutation. Clinical features, including disease onset, symptoms, biochemical metabolites, gene mutation, and follow-up outcomes were reviewed and analyzed in detail. The median follow-up period spanned 3 years and 8 months, with a range of 1 year and 2 months to 12 years and 10 months.Result s Among 195 patients carrying the c.482G > A variant, 125 (64.1%) cases were diagnosed by newborn screening (NBS), 60 (30.8%) cases were detected due to disease onset, and 10 (5.1%) cases were identified from sibling diagnoses. One hundred and seventeen (93.6%) individuals who were diagnosed by NBS, and nine patients who came from sibling diagnoses remained asymptomatic in this study. From 69 symptomatic patients of the c.482G > A group, more patients presented with later onset, and the top six common clinical symptoms at disease onset were developmental delay (59.4%), lower limb weakness and poor exercise tolerance (50.7%), cognitive decline (37.7%), gait instability and abnormal posture (36.2%), seizures (26.1%), and psychiatric and behavioral disturbances (24.6%). In the 159 symptomatic patients lacking c.482G > A variants, the most frequently observed clinical manifestations at disease onset included developmental delay (81.8%), lethargy and feeding difficulty (62.9%), lower limb weakness and poor exercise tolerance (54.7%), prolonged neonatal jaundice (51.6%), vomiting (47.2%), and seizures (32.7%). Before treatment, the levels of blood propionylcarnitine, propionylcarnitine/acetylcarnitine ratio, and homocysteine in the c.482G > A group were significantly lower (P < 0.05) than those in the non-c.482G > A group, while the concentration of urinary methylmalonic acid was slightly lower (P > 0.05). The degree of decline in the above metabolites after treatment in different groups significantly differed in both plasma total homocysteine values and urinary methylmalonic acid levels (P < 0.05). In patients carrying the c.482G > A variant compared with the non-c.428G > A group, there were markedly lower rates of mortality (0.5% vs. 2.0%) and developmental delay (20.5% vs. 65.5%). When compared with individuals diagnosed due to disease onset, those identified through NBS in either group exhibited a reduced proportion of disease onset (6.7% vs. 100% in the c.482G > A group, 54.4% vs. 100% in the non-c.482G > A group), lower mortality (0.0% vs. 1.7% in the c.482G > A group, 0.0% vs. 3.6% in the non-c.482G > A group), and had a higher percentage of patients exhibiting normal psychomotor and language development (99.3% vs. 33.3% in the c.482G > A group, 58.9% vs. 10.9% in the non-c.482G > A group).Conclusions The c.482G > A variant in MMACHC is associated with late-onset and milder phenotypes of CblC disease. Patients with this mutation tend to have a relatively better response to hydroxocobalamin, better metabolic control, and more favorable neurological outcomes. NBS and other appropriate pre-symptomatic treatments seem to be helpful in early diagnosis, resulting in favorable clinical outcomes.

Late-onset Cobalamin C Deficiency Chinese Sibling Patients with Neuropsychiatric Presentations.

Characteristics of Clinical Manifestations and Molecular Genetics of Late-Onset Cobalamin C Deficiency

The First Case of Cobalamin F Disorder in China: Report and Literature Review

Late-onset Cblc Defect: Clinical, Biochemical and Molecular Analysis

Late-onset Cblc Deficiency Around Puberty: a Retrospective Study of the Clinical Characteristics, Diagnosis, and Treatment

Clinical, Biochemical, and Molecular Analysis of Combined Methylmalonic Acidemia and Hyperhomocysteinemia (cblc Type) in China

Late-onset cobalamin C deficiency type in adult with cognitive and behavioral disturbances and significant cortical atrophy and cerebellar damage in the MRI: a case report

Variable Phenotypes and Outcomes Associated with the MMACHC C.609g>a Homologous Mutation: Long Term Follow-Up in a Large Cohort of Cases

Peripheral Nervous System Involvement in Late-Onset Cobalamin C Disease?

Easily Misdiagnosed cblC Deficiency in Adolescents: the Clinical and Metabolic Studies

Prominent Renal Complications Associated with MMACHC Pathogenic Variant C.80a > G in Chinese Children with Cobalamin C Deficiency

Variable Phenotypes and Outcomes Associated with the MMACHC C.482g > A Mutation: Follow-Up in a Large CblC Disease Cohort

Clinical data analysis of cblC methylmalonic acidemia combined with homocysteinemia

Mutation spectrum of MMACHC in Chinese pediatric patients with cobalamin C disease: A case series and literature review.

Clinical and Molecular Analysis of Cobalamin C Type Methylmalonic Aciduria with Homocystinuria in a Chinese Family

Combined Methylmalonic Aciduria and Homocystinuria Cblc Type of a Taiwanese Infant with C.609g>a and C.567dupt Mutations in the MMACHC Gene

Long-term Follow-Up of Children with Carbamoyl Phosphate Synthase 1 Deficiency Detected in Newborn Screening.

Case report: An asymptomatic mother with an inborn error of cobalamin metabolism (cblC) detected through high homocysteine levels during prenatal diagnosis

Evaluation of the clinical, biochemical, and molecular spectrum of Cobalamin C (CblC) defect in 33 patients from Pakistan

Clinical analysis and outcome of patients with c. 482G >A variant of MMACHC gene in cblC type methylmalonic acidemia

[Factors Affecting Phenotypes in the Patients with MMACHC Gene C.609g>a Homozygous Variant Cblc Type Methylmalonic Acidemia Combined with Homocysteinuria].